Diflunisal (NSAID): Less well-tolerated, needs more evidence.  TTR Silencers: Includes patisiran, vutrisiran (siRNA), and inotersen (antisense oligonucleotide) for ATTRv polyneuropathy, limited data for ATTR-CM. TTR Disrupters: Doxycycline and epigallocatechin-3-gallate not recommended as standard care. Antifibril Antibodies: Inconclusive effectiveness, in trials. Gene Editing (CRISPR-Cas9); Promising early clinical studies, sustained suppression of TTR production. Here, TTR is linked to polyneuropathy.